Antibiotic Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence

Antibiotic Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence

It is estimated that antimicrobial resistance (AMR) is responsible for nearly 5 million human deaths worldwide each year and will reach 10 million by 2050. Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) infections represent the fourth-leading cause of death attributable to an...

Full description

Bibliographic Details
Main Authors: Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, Rosaria Lionello, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Enrico Maria Trecarichi, Alessandro Russo
Format: Article
Language:English
Published: MDPI AG 2024-05-01
Series:Antibiotics
Subjects:
<i>Acinetobacter baumannii</i>
carbapenem resistance
sulbactam/durlobactam
cefiderocol
guidelines
real-world evidence
Online Access:https://www.mdpi.com/2079-6382/13/6/506

Internet

https://www.mdpi.com/2079-6382/13/6/506

Similar Items